CTOs on the Move

Telo Genomics

www.telodx.com

 
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.telodx.com
  • 101 College Street Suite 200
    Toronto, AB CAN M5G 1L7
  • Phone: 416.673.8487

Executives

Name Title Contact Details
Sherif Louis
President and Chief Technology Officer Profile

Similar Companies

ImClone Systems

ImClone Systems is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Color Genomics

Color provides a high-quality, physician-ordered, genetic test at a low cost. We include support for physicians, as well as genetic counseling as part of every purchase. Our goal is to expand physician-supported access to genetic testing for hereditary cancer risk to every person, everywhere.

Celerion Inc

Celerion Inc is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MGI PHARMA

MGI PHARMA, Inc. is a Lake Villa, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Goldfinch Bio

Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for kidney disease. Just as the goldfinch was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney disease. Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Our Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease. At Goldfinch, we`re pioneering a new approach to discover and develop therapeutics that target the molecular basis of kidney disease. We`re looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.